PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 8, 2025JAMA Network Open19 citationsOpen Access

COVID-19 mRNA Vaccination and 4-Year All-Cause Mortality Among Adults Aged 18 to 59 Years in France

View Full Paper
LSLaura SemenzatoSVStéphane Le VuJBJérémie Botton

Key Points

  • To assess the 4-year all-cause mortality in adults aged 18 to 59, comparing those vaccinated with mRNA COVID-19 vaccine to unvaccinated individuals.
  • Cohort study using data from the French National Health Data System
  • Follow-up of vaccinated and unvaccinated individuals for up to 4 years
  • Cox models adjusted for sociodemographic characteristics and comorbidities to estimate mortality
  • Entry of individuals based on mRNA vaccination dates and random index dates for unvaccinated
  • Complementary analyses on causes of death conducted until December 31, 2023.
  • A total of 22,767,546 vaccinated and 5,932,443 unvaccinated individuals were analyzed
  • Vaccinated individuals had a 25% lower risk of all-cause mortality
  • Vaccinated individuals showed a 74% reduction in risk of death from severe COVID-19
  • Mortality was 29% lower within 6 months following vaccination
  • All-cause death rates were approximately 0.4% in vaccinated and 0.6% in unvaccinated groups.

Abstract

Importance While several studies have assessed the impact of COVID-19 vaccination on short-term mortality, none have compared long-term mortality by vaccination status, particularly in young individuals who are less likely to experience severe disease following SARS-CoV-2 infection. Objective To compare 4-year all-cause mortality in individuals aged 18 to 59 years vaccinated with the mRNA COVID-19 vaccine vs unvaccinated individuals. Design, Setting, and Participants This cohort study used data from the French National Health Data System for all individuals in the French population aged 18 to 59 years who were alive on November 1, 2021. Data analysis was conducted from June 2024 to September 2025. Exposure Exposure was defined as receiving a first mRNA dose between May 1 and October 31, 2021. Individuals who were unvaccinated by November 1, 2021, were assigned a random index date based on vaccinated individuals’ vaccination dates. Main Outcomes and Measures Cox models weighted for sociodemographic characteristics and 41 comorbidities were used to estimate 4-year all-cause mortality. Time to event was censored at all-cause death, COVID-19 vaccination for unexposed individuals, or study termination on March 31, 2025. Complementary analyses were performed, including a comparison of the main causes of death available up to December 31, 2023. Follow-up began 6 months after the index date in both groups to address immortal time bias. Short-term mortality within 6 months after vaccination was assessed in a separate, independent study using adapted self-controlled case series models. Results A total of 22 767 546 vaccinated and 5 932 443 unvaccinated individuals were followed up for a median (IQR) of 45 (44-46) months. Vaccinated individuals were older than unvaccinated individuals (mean SD age, 38.0 11.8 years vs 37.1 11.4 years), more frequently women (11 688 603 51.3% vs 2 876 039 48.5%) and had more cardiometabolic comorbidities (2 126 250 9.3% vs 464 596 7.8%). During follow-up, 98 429 (0.4%) and 32 662 (0.6%) all-cause deaths occurred in the vaccinated and unvaccinated groups, respectively. Vaccinated individuals had a 74% lower risk of death from severe COVID-19 (weighted hazard ratio wHR, 0.26 95% CI, 0.22-0.30) and a 25% lower risk of all-cause mortality (wHR, 0.75 95% CI, 0.75-0.76), with a similar association observed when excluding severe COVID-19 death. Sensitivity analysis revealed that vaccinated individuals consistently had a lower risk of death, regardless of the cause. Mortality was 29% lower within 6 months following COVID-19 vaccination (relative incidence, 0.71 95% CI, 0.69-0.73). Conclusions and Relevance In this national cohort study of 28 million individuals, the results found no increased risk of 4-year all-cause mortality in individuals aged 18 to 59 years vaccinated against COVID-19, further supporting the safety of the mRNA vaccines that are widely used worldwide.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Semenzato et al. (2025) studied this question.

synapsesocial.com/papers/693624ce4fa91c937236cddahttps://doi.org/10.1001/jamanetworkopen.2025.46822
Ask AI
Helpful
Bookmark
Share
View Full Paper